All Releases
Subscribe to Medigene AG

14.01.2004 – 12:03

Medigene AG

euro adhoc: MediGene AG
MediGene and Yamanouchi Conclude Marketing and Development Partnership For Anti-Cancer Drug Leuprogel® (New Name: Eligard®) (E)

---------------------------------------------------------------------   Disclosure announcement transmitted by euro adhoc.   The issuer is responsible for the content of this announcement. ---------------------------------------------------------------------

Martinsried - San Diego, January 14, 2004. The German-American biotechnology company MediGene AG (Frankfurt, Prime Standard: MDG) has concluded a partnership with the pharmaceuticals group Yamanouchi for the commercialization in Europe of the anti-cancer drug Eligard®, previously known as Leuprogel®. Yamanouchi, the second largest pharmaceuticals company in Europe in the field of urology, will take on pan-European promotion and sale of the drug for the treatment of prostate cancer. In return MediGene will receive successive milestone payments totaling up to EUR23.5 million including a signing fee of EUR4 million, as well as royalties on sales of Eligard®.

At the beginning of December 2003, the one-month sustained release product of Leuprogel® / Eligard® received marketing authorization for Germany. The three-months product is still undergoing approval procedure by the German regulatory authorities. In April 2001, MediGene had acquired the license for Leuprogel® / Eligard®  from the US company Atrix Laboratories, Inc.  

Contact: MediGene AG, e-mail:, Fax: ++ 49 - 89 - 85 65 - 2920 Julia Hofmann, Public Relations , Phone: ++ 49 - 89 - 85 65 - 3324 Dr. Michael Nettersheim, Investor Relations, Phone: ++ 49 - 89 - 85 65 - 2946

end of announcement            euro adhoc 14.01.2004

Further inquiry note: Julia Hofmann Tel.: +49 (0)89 8565 3324 E-Mail:

Branche: Biotechnology
ISIN:      DE0005020903
WKN:        502090
Index:    CDAX, Prime All Share, Prime Standard, Technologie All Share
Börsen:  Frankfurter Wertpapierbörse / regulated dealing
              Niedersächsische Börse zu Hannover / free trade
              Berliner Wertpapierbörse / free trade
              Bayerische Börse / free trade
              Hamburger Wertpapierbörse / free trade
              Bremer Wertpapierbörse (BWB) / free trade
              Börse Düsseldorf / free trade
              Baden-Württembergische Wertpapierbörse / free trade

Original content of: Medigene AG, transmitted by news aktuell

Additional press releases: Medigene AG
Additional press releases: Medigene AG